Clinical Trials
- Breast Cancer
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
- Date11/09/2021
- Lung Cancer, Breast Cancer
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors
- Date01/13/2020
- Breast Cancer
A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Date08/31/2021
- Breast Cancer
A Safety Study of SGN-LIV1A in Breast Cancer Patients
- Ages18 years and older
- GenderFemale only
- Date06/26/2014
- Breast Cancer
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
- Date05/26/2021
- Colorectal Cancer, Stomach and Esophagus, Kidney Cancer, Head and Neck Cancers, Lung Cancer, Thyroid and Other Endocrine Cancers, Gynecological Cancers, Other Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer, Cancer, Breast Cancer
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Ages18 years and older
- GenderBoth
- Date11/20/2017
- Lung Cancer, Phase 1 Cancers, Breast Cancer, Gynecological Cancers
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors
- Date01/13/2020
- Breast Cancer
I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
- Date05/21/2018
- Colorectal Cancer, Sarcoma Cancers, Brain and Other Nervous System Cancers, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Other Cancers, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Leukemia, Melanoma, Thyroid and Other Endocrine Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
- Date08/08/2016
- Colorectal Cancer, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Melanoma, Thyroid and Other Endocrine Cancers, Other Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Phase 1 Cancers, Cancer
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Date01/04/2019